Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements

Moleculin Biotech ( (MBRX) ) just unveiled an update.

On May 23, 2025, Moleculin Biotech, Inc. was notified by Nasdaq that it was not in compliance with the exchange’s Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also failed to meet alternative standards related to market value of listed securities or net income from continuing operations. After receiving a delisting determination on November 20, 2025, and requesting a hearing, the company was informed on January 6, 2026, that it had regained compliance with all applicable Nasdaq continued listing requirements, leading to the cancellation of the scheduled hearing and removing the immediate risk of its shares being delisted from the exchange.

The most recent analyst rating on (MBRX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, heavy losses and cash burn, and negative equity) and very bearish technicals (price far below key moving averages with weak momentum). Corporate events provide some offset via positive clinical/pipeline progress and actions to improve Nasdaq compliance and equity position, but valuation support is limited due to ongoing losses and no dividend.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics, with its shares listed on the Nasdaq Capital Market, where it is subject to minimum stockholders’ equity and other continued listing standards.

Average Trading Volume: 309,605

Technical Sentiment Signal: Sell

Current Market Cap: $12.01M

Learn more about MBRX stock on TipRanks’ Stock Analysis page.